Scarica l'app Stockscreener
118.42
3.69%
-4.54
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Precedente Chiudi:
$122.96
Aprire:
$122.65
Volume 24 ore:
700.70K
Relative Volume:
1.13
Capitalizzazione di mercato:
$5.91B
Reddito:
$338.46M
Utile/perdita netta:
$-310.96M
Rapporto P/E:
-18.13
EPS:
-6.53
Flusso di cassa netto:
$-132.82M
1 W Prestazione:
-5.39%
1M Prestazione:
+12.53%
6M Prestazione:
-0.86%
1 anno Prestazione:
+29.07%
Intervallo 1D:
$117.75
$123.04
Intervallo di 1 settimana:
$117.75
$130.00
Portata 52W:
$75.56
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Confronta AXSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
118.42 | 6.19B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Iniziato | Oppenheimer | Outperform |
| 2025-04-07 | Iniziato | Jefferies | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-31 | Reiterato | Mizuho | Outperform |
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Scientech Research LLC Makes New Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - GlobeNewswire
Vident Advisory LLC Acquires New Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Adage Capital Partners GP L.L.C. Sells 12,000 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Woodline Partners LP Cuts Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Fred Alger Management LLC Takes $860,000 Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome initiated with Overweight at Wells Fargo on Alzheimer's drug potential - MSN
Axsome Therapeutics (NASDAQ:AXSM) Director Purchases $200,466.00 in Stock - MarketBeat
Axiom Investors LLC DE Invests $3.07 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome therapeutics director Coleman buys $200k+ in shares - Investing.com India
Axsome therapeutics director Coleman buys $200k+ in shares By Investing.com - Investing.com Australia
Axsome Therapeutics, Inc. $AXSM Shares Sold by Cormorant Asset Management LP - MarketBeat
Ieq Capital LLC Takes Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Will Axsome Therapeutics Inc. announce a stock splitJuly 2025 Sector Moves & Low Risk High Win Rate Picks - Lancaster City Council
Axsome Therapeutics at Morgan Stanley: Strategic Growth and Innovation By Investing.com - Investing.com Canada
Axsome Therapeutics at Morgan Stanley: Strategic Growth and Innovation - Investing.com
Sector ETF Data Correlates with Strength in Axsome Therapeutics Inc.2025 Performance Recap & Safe Entry Point Identification - beatles.ru
Roger Jeffs Sells 13,464 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Axsome Therapeutics, Inc. $AXSM is BVF Inc. IL's 2nd Largest Position - MarketBeat
Point72 Europe London LLP Has $1.76 Million Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Russell Investments Group Ltd. Has $308,000 Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
PDT Partners LLC Increases Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
What does recent volatility data suggest for Axsome Therapeutics Inc2025 Key Lessons & Reliable Breakout Forecasts - Newser
What does recent volatility data suggest for Axsome Therapeutics Inc.July 2025 Analyst Calls & Weekly Stock Breakout Alerts - Newser
Axsome therapeutics director Saad sells $1.14 million in shares By Investing.com - Investing.com Australia
Axsome therapeutics director Saad sells $1.14 million in shares - Investing.com
Ranking Axsome Therapeutics Inc. among high performing stocks via toolsQuarterly Profit Review & High Accuracy Buy Signal Tips - Newser
Applying big data sentiment scoring on Axsome Therapeutics Inc.July 2025 PreEarnings & Weekly High Momentum Picks - Newser
Landscape Capital Management L.L.C. Makes New $632,000 Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Published on: 2025-09-05 14:08:02 - Newser
Is Axsome Therapeutics Inc. a stock for growth or value investorsWeekly Profit Recap & High Conviction Buy Zone Picks - خودرو بانک
Best data tools to analyze Axsome Therapeutics Inc. stockTrade Signal Summary & Technical Pattern Alert System - Newser
Using AI based signals to follow Axsome Therapeutics Inc.July 2025 Pullbacks & Weekly High Return Opportunities - Newser
Why Axsome Therapeutics Inc. is moving today2025 Historical Comparison & Smart Investment Allocation Tips - Newser
Custom watchlist performance reports with Axsome Therapeutics Inc.Weekly Investment Report & Fast Entry Momentum Alerts - Newser
Multi asset correlation models including Axsome Therapeutics Inc.Earnings Trend Report & High Conviction Investment Ideas - Newser
Axsome Therapeutics at Cantor Conference: Strategic Growth in Brain Health By Investing.com - Investing.com Canada
Driehaus Capital Management LLC Makes New Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Is Axsome Therapeutics Inc.’s growth already priced inCPI Data & Safe Swing Trade Setup Alerts - khodrobank.com
Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years - The Globe and Mail
Will Axsome Therapeutics Inc. bounce back from current supportWeekly Gains Summary & High Return Trade Opportunity Guides - Newser
Forecasting Axsome Therapeutics Inc. price range with options dataJuly 2025 Review & Weekly High Potential Alerts - Newser
Wells Fargo Initiates Coverage on Axsome Therapeutics with Overweight Rating and $163 Price Target - AInvest
Relative strength of Axsome Therapeutics Inc. in sector analysisQuarterly Portfolio Review & Long-Term Safe Investment Plans - Newser
Sector ETF performance correlation with Axsome Therapeutics Inc.Volume Spike & Proven Capital Preservation Methods - Newser
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Axsome Therapeutics Inc Azioni (AXSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Coleman Mark | Director |
Sep 08 '25 |
Buy |
127.28 |
1,575 |
200,466 |
48,212 |
| Saad Mark E | Director |
Sep 05 '25 |
Option Exercise |
9.00 |
9,127 |
82,143 |
19,129 |
| Saad Mark E | Director |
Sep 05 '25 |
Sale |
125.07 |
9,127 |
1,141,514 |
10,002 |
0.93%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):